The global assisted reproductive technology (ART) field is facing a growing
challenge of diminished ovarian reserve (DOR), particularly among women over 35,
driving demand for personalized and effective ovulation induction regimens. As a
classic dual-hormone (FSH+LH) preparation, Human Menopausal Gonadotropin (HMG)
has evolved beyond traditional applications, with recent clinical evidence
highlighting its optimized efficacy through precise timing in the follicular
phase. Kangyuan, a leader in reproductive hormone innovation, is advancing
high-purity Human Menopausal Gonadotropin solutions tailored for DOR patients,
redefining treatment outcomes in precision ART therapy.
The breakthrough in Human Menopausal Gonadotropin application lies in
targeted supplementation during the middle and late follicular phase for DOR
patients. A clinical study involving 682 elderly DOR patients confirmed that
adding HMG when the dominant follicle reaches 10-14mm significantly improves
treatment outcomes compared to no supplementation or early addition3. The middle-late supplementation group achieved a clinical pregnancy rate
of 45.1% in fresh cycles, far exceeding the 27.7% of the non-supplementation
group, while also increasing the number of mature oocytes and usable embryos3. This precision timing leverages Human Menopausal
Gonadotropin’s balanced FSH-LH ratio to enhance follicular maturation without
excessive ovarian stimulation, addressing the core need of DOR patients for
efficient ovulation induction.
Kangyuan’s Human Menopausal Gonadotropin stands out with high-purity
production technology, breaking through the limitations of traditional
urinary-derived preparations. Originating from menopausal women’s urine—a
natural source rich in FSH and LH2—our products adopt
advanced multi-step chromatography purification and viral inactivation
processes, achieving a purity of over 99% and eliminating urinary-derived
impurities. This high-purity standard ensures consistent bioactivity, with the
U.S. Society for Reproductive Medicine confirming that modern high-purity
urinary HMG matches recombinant FSH in safety and efficacy2.
For DOR patients sensitive to hormone fluctuations, this stability reduces
adverse reactions while maximizing therapeutic effects.
Beyond efficacy optimization, Kangyuan’s Human Menopausal Gonadotropin
addresses unmet needs in accessibility and compliance. Traditionally, imported
reproductive hormones are costly, placing a heavy burden on patients5. Our locally developed high-purity HMG, compliant with USP and EP
standards, offers a cost-effective alternative without compromising quality. We
provide flexible dosages (75IU, 150IU vials) to match the precision
supplementation protocol, enabling clinicians to adjust doses based on
follicular development dynamics. With EU GMP certification and FDA DMF filings,
our Human Menopausal Gonadotropin supports global market access, catering to the
growing demand for DOR-targeted ART solutions worldwide.
As the prevalence of DOR rises globally, Human Menopausal Gonadotropin’s
role in precision follicular phase supplementation becomes increasingly pivotal.
Kangyuan remains committed to translating clinical evidence into accessible
therapies, combining high-purity production technology with patient-centric
formulation design. Our professional team provides tailored technical support,
helping ART centers optimize HMG supplementation timing for DOR patients and
improve treatment success rates. Whether you’re an ART clinic specializing in
elderly infertility, a distributor expanding reproductive hormone portfolios, or
a researcher exploring precision ovulation induction, Kangyuan is your trusted
partner. Contact us today to explore our Human Menopausal Gonadotropin solutions
and elevate DOR treatment outcomes.